Abstract: The compounds and methods of the present disclosure exhibit induce Ucp1 transcription, enhance of mitochondrial respiration, activate protein kinase A, increase lipolysis, and increase p38 MAPK phosphorylation in cells, particularly brown adipocytes and white adipocytes. They also protect primary cardiomyocytes against hypertrophy induced by adrenergic agonists. Such compounds and methods are useful in the treatment and prevention of conditions such as obesity and associated complex metabolic, endocrine, and hemodynamic changes, as well as related conditions as dyslipidemias, cardiovascular disease, and type 2 diabetes.

Abstract: Disclosed herein are methods for (a) treating, inhibiting, or reducing aging of a subject, (b) treating, inhibiting, or reducing an age-related symptom or an age-related disease in a subject, and/or (c) increasing the lifespan of a subject which comprise administering to the subject one or more ketobutyrate compounds and compositions thereof.

Abstract: Disclosed herein are methods of preventing, inhibiting, reducing, or treating ischemia and reperfusion injury to tissues with glutarate compounds such as ?-ketoglutarate.

Abstract: Disclosed herein are methods of preventing, inhibiting, reducing, or treating ischemia and reperfusion injury to tissues with glutarate compounds such as ?-ketoglutarate.

Abstract: Disclosed herein are methods for (a) inhibiting, reducing, slowing, or preventing, the aging of a subject, (b) for treating, inhibiting, reducing, or preventing an age-related disease in the subject, and/or (c) for increasing the lifespan of the subject which comprise administering to the subject one or more glutarate compounds, such as ?-ketoglutate, and/or one or more glutamate compounds, such as 2-hydroxypentanedioate, and compositions thereof.

Abstract: Disclosed herein are methods of preventing, inhibiting, reducing, or treating ischemia and reperfusion injury to tissues with glutarate compounds such as ?-ketoglutarate.

Abstract: Disclosed herein are methods of preventing, inhibiting, reducing, or treating ischemia and reperfusion injury to tissues with glutarate compounds such as ?-ketoglutarate.

Abstract: Disclosed herein are methods for (a) treating, inhibiting, or reducing aging of a subject, (b) treating, inhibiting, or reducing an age-related symptom or an age-related disease in a subject, and/or (c) increasing the lifespan of a subject which comprise administering to the subject one or more ketobutyrate compounds and compositions thereof.

Abstract: Disclosed herein are methods for (a) inhibiting, reducing, slowing, or preventing, the aging of a subject, (b) for treating, inhibiting, reducing, or preventing an age-related disease in the subject, and/or (c) for increasing the lifespan of the subject which comprise administering to the subject one or more glutamate compounds, such as ?-ketoglutate, and/or one or more glutamate compounds, such as 2-hydroxypentanedioate, and compositions thereof.

Abstract: This invention pertains to the identification and isolation of a gene implicated in the fatty liver dystrophy (fld) phenotype. Mouse and human forms of the novel gene, designated herein as Lpin1/LPIN1 (mouse and human genes, respectively), are identified. This invention additionally provides methods of screening for agents that alter adipose tissue development. The methods involve contacting a cell containing a Lpin1 gene with a test agent; and detecting a change in the expression or activity of a Lpin1 gene product, where a difference in the expression or activity of Lpin1 in the contacted cell indicates that the agent alters or is likely to alter adipose tissue development. Also provided are methods of identifying Lpin1 mutations, and methods of mitigating symptoms of lipodystrophy, obesity, diabetes, atherosclerosis and related pathologies.

Abstract: This invention pertains to the identification and isolation of a gene implicated in the fatty liver dystrophy (fld) phenotype. Mouse and human forms of the novel gene, designated herein as Lpin1/LPIN1 (mouse and human genes, respectively), are identified. This invention additionally provides methods of screening for agents that alter adipose tissue development. The methods involve contacting a cell containing a Lpin1 gene with a test agent; and detecting a change in the expression or activity of a Lpin1 gene product, where a difference in the expression or activity of Lpin1 in the contacted cell indicates that the agent alters or is likely to alter adipose tissue development. Also provided are methods of identifying Lpin1 mutations, and methods of mitigating symptoms of lipodystrophy, obesity, diabetes, atherosclerosis and related pathologies.